All In MedTech

Device Trial Radar · NCT05773963

A Post-market Study to Evaluate the Effects of Sodium Hyaluronate Based Eye Drops in Patients Affected by Dry Eye Disease

A Post-market Study to Evaluate the Effects of Sodium Hyaluronate Based Eye Drops in Patients Affected by Dry Eye Disease.

Last checked: Nov 20, 2026Latest source record: May 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

80

Actual

Start

Feb 24, 2022

Primary completion

Jun 25, 2024

Study completion Jun 25, 2024

Sponsor

Lead sponsor
Montefarmaco OTC SpANot on our public-company list
Sponsor type
Industry
First posted
Mar 17, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Dry eye disease (DED), also called keratoconjunctivitis sicca, is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film and accompanied by symptoms such as ocular discomfort and visual disturbance. The reported prevalence of DED estimates vary widely, from 5% to 33%, which may reflect both differing populations and inconsistent diagnostic criteria. Patients with moderate-to-severe DED may experience a reduced quality of life due to ocular pain, difficulty in performing daily activities, and depression. First-line therapy for treating dry eye consists of over the counter (OTC) artificial tear drops, gels, ointments, or lubricants. Sodium hyaluronate (commonly referred to as hyaluronic acid or HA) is a naturally occurring polymer and is ubiquitous throughout the interstitial cellular space in humans. It helps retain moisture in different types of tissue throughout the human body and aids lubrication between layers of tissue to eliminate friction - thus making it an ideal physiological tear film substitute. As a result of its coiled structure and large hydrophilic domains, HA attracts and retains a large amount of water, and therefore possesses the ability to retard water evaporation. Following instillation, HA-based solutions effectively moisturize the eye surface and prolong the beneficial wetting effect over time. Hyaluronic acid does not alter the normal surface of the eye like other types of tear substitutes. It closely mimics the properties of a normal, healthy tear film, with a longer retention time on the corneal surface than a cellulose-based tear substitute. HA gels have also been used successfully in ophthalmic surgery for many years. As a result of their unique physical and chemical properties, HA solutions are similar to natural tears. For that reason, they are widely used in ophthalmology as lubricant eye drops for the treatment of sensations of ocular dryness. For these reasons, an interventional, confirmative, post marketing clinical follow-up (PMCF) study was planned to evaluate the performance and safety of HA-based ophthalmic solutions (i.e. Irilens; Iridina; Afomill Lubricating Eye Drops) used to relieve dry eyes symptoms. The objectives of this PMCF study are confirmation of the performance, collection of additional safety data regarding expected adverse events and detection of potential unexpected adverse events associated with use of three investigational products (IPs) containing HA as key ingredient. The IPs are on the market with the following brand names: * Irilens; * Iridina; * Afomill Lubricating Eye Drops. Primary • To evaluate the performance of IPs used as intended to relieve dry eye symptoms. Secondary * To evaluate the efficacy of IPs used as intended to relieve symptoms of DED. * To evaluate the safety and tolerability of the IPs. * To evaluate the patient satisfaction of the IPs.

Conditions

  • Opthalomology/Dry Eye

Interventions

  • Irilens; Iridina; Afomill Lubricating Eye DropsDevice

    * Irilens (with 0.4% HA as key ingredient); * Iridina (with 0.4% HA as key ingredient); * Afomill Lubricating Eye Drops (with 0.2% HA as key ingredient and distilled water of Chamomile).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the performance of Investigational Products to relieve symptoms of dry eye. The performance will be evaluated by Shirmer I test at baseline (V0) and end of study visit (change will be assessed)Time frame: Day 0 (baseline visit the IP will be dispensed) and Day 25

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • IRCCS Istituto Auxologico Italiano

    Milan, Italy

  • Ospedale Felice Liotti Pontedera

    Pisa, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.